Abstract
Advances in the sophisticated instruments for the isolation and characterization of marine natural products, and development in the biological assay systems, have resulted in the discovery of various compounds of biomedical application. Marine natural products have been a source of new leads for the treatment of many deadly diseases such as cancer, acquired immuno-deficiency syndrome (AIDS) etc. The compounds of marine origin are diverse in structural class from simple linear peptides to complex macrocyclic polyethers. Number of marine peptides have been isolated in recent years which exhibit potent biological activities, and many of the compounds showed promising anticancer activity. Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer, and other anticancer peptides such as kahalalide F, hemiasterlin, dolastatins, cemadotin, soblidotin, didemnins and aplidine have entered in the clinical trials. Clinical status of anticancer marine derived pep tides have been discussed and reviewed.
Keywords: Kahalalide F, Hemiasterlin, Dolastatins, Cemadotin, Soblidotin, Didemnins, Aplidine
Anti-Cancer Agents in Medicinal Chemistry
Title: Marine Peptides and Related Compounds in Clinical Trial+
Volume: 6 Issue: 1
Author(s): Diwan S. Rawat, Mukesh C. Joshi, Penny Joshi and Himanshu Atheaya
Affiliation:
Keywords: Kahalalide F, Hemiasterlin, Dolastatins, Cemadotin, Soblidotin, Didemnins, Aplidine
Abstract: Advances in the sophisticated instruments for the isolation and characterization of marine natural products, and development in the biological assay systems, have resulted in the discovery of various compounds of biomedical application. Marine natural products have been a source of new leads for the treatment of many deadly diseases such as cancer, acquired immuno-deficiency syndrome (AIDS) etc. The compounds of marine origin are diverse in structural class from simple linear peptides to complex macrocyclic polyethers. Number of marine peptides have been isolated in recent years which exhibit potent biological activities, and many of the compounds showed promising anticancer activity. Didemnin was the first marine peptide that entered in human clinical trials in US for the treatment of cancer, and other anticancer peptides such as kahalalide F, hemiasterlin, dolastatins, cemadotin, soblidotin, didemnins and aplidine have entered in the clinical trials. Clinical status of anticancer marine derived pep tides have been discussed and reviewed.
Export Options
About this article
Cite this article as:
Rawat S. Diwan, Joshi C. Mukesh, Joshi Penny and Atheaya Himanshu, Marine Peptides and Related Compounds in Clinical Trial+, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (1) . https://dx.doi.org/10.2174/187152006774755519
DOI https://dx.doi.org/10.2174/187152006774755519 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current and Potential Anticancer Drugs Targeting Members of the UHRF1 Complex Including Epigenetic Modifiers
Recent Patents on Anti-Cancer Drug Discovery Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews Rac-1 as a New Therapeutic Target in Cerebro- and Cardio-Vascular Diseases
Current Drug Targets Exploring the use of Estrogen & Progesterone Replacement Therapy in Subarachnoid Hemorrhage
Current Drug Safety What Fans the Fire: Insights into Mechanisms of Leptin in Metabolic Syndrome- Associated Heart Diseases
Current Pharmaceutical Design Differential Expression of MARK4 Protein and Related Perturbations in Females with Ovulatory PCOS
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytokines in Colitis-Associated Cancer: Potential Drug Targets?
Inflammation & Allergy - Drug Targets (Discontinued) microRNA Decay: Refining microRNA Regulatory Activity
MicroRNA Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management
Current Drug Safety Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry
Current Medicinal Chemistry Site-related Effects of Relaxin in the Gastrointestinal Tract Through Nitric Oxide Signalling: An Updated Report
Current Protein & Peptide Science Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Carotenoids and Cardiovascular Risk
Current Pharmaceutical Design Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry A State-of-the-art Review and Prospective Therapeutic Applications of Prenyl Flavonoids as Chemosensitizers against Antifungal Multidrug Resistance in <i>Candida albicans</i>
Current Medicinal Chemistry Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging Heparin-Binding Proteins (Chemokines and Defensins) and their Complexes with Glycosaminoglycans from the Solution NMR Perspective
Current Protein & Peptide Science Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets Selective Serotonin Re-Uptake Inhibitors for the Treatment of Depression in Coronary Artery Disease and Chronic Heart Failure: Evidence for Pleiotropic Effects
Cardiovascular & Hematological Agents in Medicinal Chemistry